Archives
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
The reductase activity in patients with OHD as assessed by
2024-07-10

The 5α-reductase activity in patients with 21-OHD, as assessed by the 5α-THF to 5β-THF (ratio 3) and by the 5α-17HP to 17HP (ratio 4) ratios, showed a similar pattern of activities (Fig. 2A–C) and significant correlations (ratio 1 vs. ratio 3; rs=0.67; pAUY-922 to the 5α-reducase activity, the acti
-
br Materials and methods br Results br Discussion
2024-07-10

Materials and methods Results Discussion Author contributions JH purified protein, performed vanadate inhibition experiments, crystallized, collected data, determined and refined the ATX-VO5 structure, analysed all the structures, prepared the displayed items and supervised ALHE; WJK con
-
br Conclusion br Acknowledgement This study was
2024-07-10

Conclusion Acknowledgement This study was supported by NIH/NINDSR01 NS036812-16. Introduction Stroke is the leading cause of disability and the fifth leading cause of death in the United States (Writing Group et al., 2016). On average, every 4 min a human dies of stroke (Lackland et al., 2
-
Previous studies demonstrate that chiral biointerface has
2024-07-10

Previous studies demonstrate that chiral biointerface has great influence on cells adhesion and proteins adsorption [39], [40], [41], [42], [43], which inspired us to further develop antimicrobial materials or surfaces by taking advantage of the “chiral taste” of microbes. L-borneol is a hydrophobic
-
Introduction A defining feature of cancer cells is disruptio
2024-07-09

Introduction A defining feature of cancer cells is disruption of the normal controls of the cell cycle; a tumor suppressor or inhibitor may act by restricting progression of the cell cycle. P27 (also known as cyclin-dependent kinase inhibitor 1B, P27, or Kip1) is a putative cell-cycle inhibitor pro
-
Brefeldin A br AHR mediates TCDD toxicity and wasting
2024-07-09

AHR mediates TCDD toxicity and wasting syndrome TCDD causes numerous toxicities in laboratory animals, including teratogenesis, hepatic steatosis, thymic atrophy, immune dysfunction and a lethal wasting syndrome [17]. The dose-dependent sensitivity to TCDD-induced toxicities varies widely among l
-
Because activation of HT A receptor is capable of
2024-07-09

Because activation of 5-HT2A receptor is capable of facilitating dopamine cell activity and dopamine release (Bortolozzi et al., 2003), and this action of dopamine is known to mediate rat maternal behavior, especially maternal motivation (Afonso et al., 2007, Febo et al., 2010, Li and Fleming, 2003,
-
Further analysis sought to understand the mechanism
2024-07-09

Further analysis sought to understand the mechanism associated with the autotaxin-mediated increase of miR-489-3p in circulation. Based upon sequence complementarity, DIANA TarBase predicted miR-489-3p targets MAPK2K1, or MEK1, an oncogene widely dysregulated in cancer (Fig. 4A). To test this relati
-
shows the complexes resulting from
2024-07-08

shows the complexes resulting from interaction of the proposed anion receptors with the anions F, Cl, NO, and SO. No imaginary frequency was observed for the optimized complexes indicating the complexes are in potential minima and they are not transition state structures. summarizes the calculate
-
The growth of cancer can control by inhibiting
2024-07-08

The growth of cancer can control by inhibiting the rate of cell proliferation or increasing the rate of selective apoptosis and effectiveness of anticancer agents varies according to genetic constitution of cancer. Hence, we investigated the anticancer activity of arginase against different kinds of
-
nae inhibitor To further evaluate the influence of antibioti
2024-07-08

To further evaluate the influence of nae inhibitor on allergy, Russel et al. initiated vancomycin treatment during pregnancy in mice and continued it for several weeks after birth. This resulted in exaggerated OVA-induced allergic inflammation, characterized by higher numbers of lung eosinophils, e
-
br Combination Effective RAS inhibition which is important f
2024-07-08

Combination Effective RAS inhibition, which is important for 777 symbolism control as well for the management of associated illnesses, can be produced through proper selection and dose maintenance and also by the combination with other antihypertensive agents along with continuous monitoring for
-
The zinc transporter proteins are members of the SLC
2024-07-08

The zinc transporter proteins are members of the SLC superfamily of metal transporters, and comprise two structurally and functionally different groups, the zinc-importer (ZIP; Zrt-, Irt-like proteins) family (SLC39A), which regulate zinc transport into the cytoplasm from outside the cell and from i
-
Introduction The burden of cardiovascular disease
2024-07-08

Introduction The burden of cardiovascular disease (CVD) is undisputed, accounting for approximately a third of global deaths (17.5 million people in 2012) (WHO, 2012). Atherosclerosis leads to the development of coronary heart disease (CHD) which accounts for more than 40% of these deaths (WHO, 201
-
The most common adverse effects were
2024-07-08

The most common adverse effects were ARIA, which occurred at higher levels than in any previous anti-Aβ mAb study. ARIA-E was observed at some point during the trial in no participants in the placebo group compared with 1 (3%), 2 (6%), 11 (37%), and 13 (41%) participants receiving 1, 3, 6, and 10 mg
16222 records 133/1082 page Previous Next First page 上5页 131132133134135 下5页 Last page